The use of Simvastatin also showed marked suppression of IL-17A and IL-22 secretion which may contribute to decrease in IL-6 and CXCL8 production in the airways of COPD patients (Fig. 5)26. This evidence concerns the gene IL22 and chronic obstructive pulmonary disease.